NCT02423265.

Trial name or title	NCT02423265
Methods	Study design: parallel‐group trial Duration of follow‐up: 9 weeks Method of randomisation: not described Method of concealment of allocation: not described Blinding: Double‐blind (Subject, Investigator, Outcomes Assessor) Power calculation: not mentioned Phases of the study: 2 (treatment phase, follow‐up phase)
Participants	Country of enrolment: not described Setting/location: not specified Diagnostic criteria (stable angina pectoris): not described Comorbidities: percutaneous coronary intervention plus stent implantation Inclusion criteria: Angiographically proven coronary artery disease with chronic stable angina for at least 3 months. Abnormal stress test (treadmill ECG, nuclear stress test, dobutamine stress echocardiogram or stress perfusion cardiac MRI) ≥ 1 chronically occluded coronary artery of a dominant coronary vessel or the left anterior descending artery and/or ≥ 1 occluded vein graft to chronically occluded native coronary vessel Subjects must be taking a minimum of 2 anti‐anginal agents Exclusion criteria: LVEF < 40 Terminal illness such as cancer Occluded recessive coronary vessel Hepatic insufficiency, Liver cirrhosis, Prolonged QT interval on ECG, Severe renal failure (see below), Excluding patients with CrCl < 30 Drugs that are strong inhibitors of CYP3A such as, ketoconazole, macrolide antibiotics and HIV protease inhibitors. Limit Ranolazine to 500 mg BID in patients on concurrent diltiazem/verapamil Limit concurrent simvastatin to 20 mg/day Limit concurrent metformin to 1700 mg/day Inability to have an MRI scan/known claustrophobia
Interventions	Number of intervention groups: 3 Concomitant medications: standard therapy (not described) Excluded medications: not mentioned Placebo group Intervention:placebo with up‐titration after 1 week Duration of intervention: 9 weeks Ranolazine group Intervention: ranolazine (type of formulation not specified) 1000 mg twice daily (up‐titrated after 1‐week 500 mg twice daily) Duration of intervention: 9 weeks
Outcomes	Total number of outcomes: 4 (cardiac MRI strain, dobutamine wall motion scoring index, quality of life, ETT parameters) OUTCOMES Quality of life Outcome definition: measured with 3 scales (SAQ, DASI, SF‐12) Method and unit of measurement: total score Time points to report: 9 weeks
Starting date	June 2015
Contact information	Ashesh N Buch, MB.ChB, M.D. bucha@ecu.edu
Notes